Literature DB >> 29375699

microRNA-503 suppresses the migration, proliferation and colony formation of prostate cancer cells by targeting tumor protein D52 like 2.

Yuhua Chi1, Feng Ding2, Wenjie Zhang1, Lifa Du1.   

Abstract

The present study investigated the expression of microRNA-503 (miR-503) and its effect and mechanism of action on prostate cancer. Tumor tissues and tumor-adjacent tissues were collected from 20 patients with prostate cancer. TargetScan was used to predict the miRNA molecule that interacts with tumor protein D52 like 2 (TPD52L2). DU145 cells were transfected with a negative control, miR-503 mimic or miR-503 inhibitor. DU145 cells that had not undergone transfection were used as a control. Levels of miR-503 and TPD52L2 mRNA were determined using reverse transcription-quantitative polymerase chain reaction and the expression of TPD52L2 protein was measured using western blot analysis. The migration ability of DU145 cells was evaluated using a Transwell assay and cell proliferation was examined using an MTT assay. A flat plate colony formation test was conducted to examine the colony formation rate of DU145 cells. The current study demonstrated that TPD52L2 expression is increased while miR-503 expression is decreased in prostate cancer tissues. Overexpression of miR-503 inhibited the transcription and translation of TPD52L2 in DU145 cells and reduced cell migration, proliferation and colony formation. By contrast, inhibition of miR-503 expression increased the expression of TPD52L2 in DU145 cells and increased cell migration, proliferation and colony formation. The present study demonstrated that miR-503 is an oncogene that regulates the migration, proliferation and colony formation of prostate cancer cells by targeting the TPD52L2 gene. Thus, miR-503 has the potential to become a target for the molecular treatment and prognosis of prostate cancer in the future.

Entities:  

Keywords:  DU145 cells; microRNA-503; prostate cancer; tumor protein D52 like 2

Year:  2017        PMID: 29375699      PMCID: PMC5763732          DOI: 10.3892/etm.2017.5401

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  31 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  Lentivirus-mediated TPD52L2 depletion inhibits the proliferation of liver cancer cells in vitro.

Authors:  Ze-Ya Pan; Yun Yang; Hao Pan; Jin Zhang; Hui Liu; Yuan Yang; Gang Huang; Lei Yin; Jian Huang; Wei-Ping Zhou
Journal:  Int J Clin Exp Med       Date:  2015-02-15

Review 3.  MicroRNA history: discovery, recent applications, and next frontiers.

Authors:  Maria I Almeida; Rui M Reis; George A Calin
Journal:  Mutat Res       Date:  2011-03-30       Impact factor: 2.433

4.  MicroRNA‑34a/c function as tumor suppressors in Hep‑2 laryngeal carcinoma cells and may reduce GALNT7 expression.

Authors:  Wei Li; Huiping Ma; Ji Sun
Journal:  Mol Med Rep       Date:  2014-01-30       Impact factor: 2.952

5.  MiR-503 targets PI3K p85 and IKK-β and suppresses progression of non-small cell lung cancer.

Authors:  Yi Yang; Lei Liu; Ying Zhang; Hongyu Guan; Jueheng Wu; Xun Zhu; Jie Yuan; Mengfeng Li
Journal:  Int J Cancer       Date:  2014-03-27       Impact factor: 7.396

6.  c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism.

Authors:  Ping Gao; Irina Tchernyshyov; Tsung-Cheng Chang; Yun-Sil Lee; Kayoko Kita; Takafumi Ochi; Karen I Zeller; Angelo M De Marzo; Jennifer E Van Eyk; Joshua T Mendell; Chi V Dang
Journal:  Nature       Date:  2009-02-15       Impact factor: 49.962

7.  MicroRNA-503 targets FGF2 and VEGFA and inhibits tumor angiogenesis and growth.

Authors:  Bisheng Zhou; Ruihua Ma; Wenxia Si; Sisi Li; Yan Xu; Xin Tu; Qing Wang
Journal:  Cancer Lett       Date:  2013-01-22       Impact factor: 8.679

8.  Identification of novel DNA-methylated genes that correlate with human prostate cancer and high-grade prostatic intraepithelial neoplasia.

Authors:  J M Devaney; S Wang; S Funda; J Long; D J Taghipour; R Tbaishat; P Furbert-Harris; M Ittmann; B Kwabi-Addo
Journal:  Prostate Cancer Prostatic Dis       Date:  2013-07-30       Impact factor: 5.554

9.  Tumor protein D52 expression and Ca2+-dependent phosphorylation modulates lysosomal membrane protein trafficking to the plasma membrane.

Authors:  Diana D H Thomas; Christina L Martin; Ning Weng; Jennifer A Byrne; Guy E Groblewski
Journal:  Am J Physiol Cell Physiol       Date:  2009-12-23       Impact factor: 4.249

10.  [The reversing and molecular mechanisms of miR-503 on the drug-resistance to cisplatin in A549/DDP cells].

Authors:  Yi Wu; Lili Guo; Jinghao Liu; Renwang Liu; Minghui Liu; Jun Chen
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2014-01
View more
  5 in total

1.  MicroRNA-503 serves an oncogenic role in retinoblastoma progression by directly targeting PTPN12.

Authors:  Yang Cheng; Wei Liu
Journal:  Exp Ther Med       Date:  2019-07-19       Impact factor: 2.447

2.  Effect of the whole seamless connection of nursing from WeChat interactive platform on stigma and quality of life in patients with urinary system cancer.

Authors:  Haiyan Hao; Xinyu Yang; Huixia Zhu; Ziheng Wang; Haiyan Zhang; Chunxia Huang
Journal:  Digit Health       Date:  2022-05-26

3.  The Antitumor Effect of TPD52L2 Silencing on Oxaliplatin-Resistant Gastric Carcinoma Is Related to Endoplasmic Reticulum Stress In Vitro.

Authors:  Yu Zhang; Dejun Yang; Ziran Wei; Xin Zhang; Zunqi Hu; Hongbing Fu; Jiapeng Xu; Weijun Wang
Journal:  Evid Based Complement Alternat Med       Date:  2022-01-18       Impact factor: 2.629

4.  MicroRNA-194 regulates cell viability and apoptosis by targeting CDH2 in prostatic cancer.

Authors:  Song Gao; Zhiying Zhao; Rong Wu; Lina Wu; Xin Tian; Zhenyong Zhang
Journal:  Onco Targets Ther       Date:  2018-08-14       Impact factor: 4.147

5.  miR-1284 Inhibits the Growth and Invasion of Breast Cancer Cells by Targeting ZIC2.

Authors:  Pengcheng Zhang; Fang Yang; Qin Luo; Daxue Yan; Shengrong Sun
Journal:  Oncol Res       Date:  2018-08-03       Impact factor: 5.574

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.